Lazard Asset Management LLC Has $549,000 Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Lazard Asset Management LLC lifted its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 122.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 171,694 shares of the company's stock after acquiring an additional 94,514 shares during the quarter. Lazard Asset Management LLC owned approximately 0.14% of Organogenesis worth $549,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of Organogenesis during the 4th quarter worth approximately $38,000. Palumbo Wealth Management LLC bought a new position in shares of Organogenesis during the 4th quarter worth approximately $65,000. Algert Global LLC bought a new position in shares of Organogenesis during the 4th quarter worth approximately $69,000. PDT Partners LLC bought a new position in shares of Organogenesis during the 4th quarter worth approximately $110,000. Finally, Aquatic Capital Management LLC bought a new position in shares of Organogenesis during the 4th quarter worth approximately $111,000. 49.57% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Morgan Stanley lifted their price target on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Stock Performance

NASDAQ:ORGO traded up $0.07 during mid-day trading on Tuesday, hitting $2.97. 875,106 shares of the stock were exchanged, compared to its average volume of 1,174,558. The stock has a market capitalization of $376.76 million, a price-to-earnings ratio of -49.50 and a beta of 1.85. The firm's 50-day simple moving average is $4.13 and its 200 day simple moving average is $3.91. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis Holdings Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). The firm had revenue of $86.69 million for the quarter, compared to analyst estimates of $90.77 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. As a group, equities analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the transaction, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. The trade was a 13.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 36.90% of the stock is currently owned by insiders.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.